BiotechTube

Anifrolumab

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Systemic Lupus Erythematosus

Conditions

Systemic Lupus Erythematosus

Trial Timeline

Jan 16, 2026 → Aug 31, 2027

NCT ID
NCT06594068

About Anifrolumab

Anifrolumab is a approved stage product being developed by AstraZeneca for Systemic Lupus Erythematosus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06594068. Target conditions include Systemic Lupus Erythematosus.

What happened to similar drugs?

9 of 20 similar drugs in Systemic Lupus Erythematosus were approved

Approved (9) Terminated (4) Active (8)
✅Baricitinib + CyclophosphamideEli LillyApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅EfalizumabMerckApproved
✅AmbrisentanGilead SciencesApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved
✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (13)

NCT IDPhaseStatus
NCT04750057Pre-clinicalCompleted
NCT07431775Pre-clinicalRecruiting
NCT07430306Phase 3Recruiting
NCT07000110Pre-clinicalRecruiting
NCT06594068ApprovedRecruiting
NCT07330245Pre-clinicalRecruiting
NCT06795893Pre-clinicalRecruiting
NCT06659029Pre-clinicalRecruiting
NCT06673043Pre-clinicalRecruiting
NCT06662123Phase 1Completed
NCT06374212Phase 2Active
NCT05339100Phase 1Completed
NCT05001698Phase 1Completed

Competing Products

20 competing products in Systemic Lupus Erythematosus

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 2
35
E6742EisaiPhase 1/2
32
KHK4827Kyowa KirinPhase 1
29
KHK4827 + PlaceboKyowa KirinPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + CyclophosphamideEli LillyApproved
47
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29